Trio of gene editing programs marks Vertex’s last additions from fruitful CRISPR deal

Vertex has opted in to three programs discovered under its 2015 deal with CRISPR Therapeutics, spending $30 million up front to gain exclusive, worldwide rights to develop gene therapies

Read the full 294 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE